Novo A/S, the holding company in the Novo Group, is responsible for the management of the assets of the Novo Nordisk Foundation, which are currently valued at more than USD 30 billion. Novo A/S is a private limited liability company fully owned by the Novo Nordisk Foundation. Besides being the major shareholder in Novo Nordisk A/S and Novozymes A/S, Novo A/S provides seed and venture capital to development stage companies and takes significant ownership positions in well-established companies, within life science and biotechnology, as well as manages a broad portfolio of financial assets.


The wellcome trust

The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It is independent of both political and commercial interests.

New paradigm in clinical stroke studies

Clinical studies of ischemic stroke are currently undergoing exciting changes, in particular with the ability of early onset treatment. Recently seminal examples of this have been published including the PHANTOM-S, MR CLEAN, and FAST-MAG studies. This provides an exciting perspective for new treatment of ischemic stroke.

Getting chemistry and biology to communicate

Copenhagen Spin-outs features an in-depth profile of Avilex Pharma and its CEO/CSO Kristian Strømgaard.

Read More

© Copyright 2021 Avilex Pharma. All rights reserved.
Avilex Pharma, Ole Maaløes Vej 3, 2200 Copenhagen, DK